Name | Edrecolomab |
---|
Description | Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research[1][2]. |
---|---|
Related Catalog | |
In Vitro | Edrecolomab (0-100 μg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC)[1]. Cell Cytotoxicity Assay[1] Cell Line: KATO III cells Concentration: 0-100 μg/mL Incubation Time: 20 hours Result: Exhibited an ED50 value>100 ng/ml. |
In Vivo | Edrecolomab (intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model[1]. Animal Model: Male nu/nu mice injected with HT-29 colon carcinoma cells[1] Dosage: 30 μg/dose Administration: Intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation Result: Inhibited tumor growth with a number of significant readings (p≤0.05). |
References |
No Any Chemical & Physical Properties |